Announced details
Treatment of dry eye disease associated with meibomian gland dysfunction (MGD)
The trial was conducted by Maruho Co., Ltd., and we received a report confirming completion of the final subject observation. Capital and personnel relationships: Not disclosed.
Head office: Kita-ku, Osaka; Representative Director and President: Sugita Jun (杉田 淳). Other details: Not disclosed.
There will be no direct impact on our results for the fiscal year ending March 2027. However, we believe this will contribute to enhancing the value of our pipeline and strengthening the foundation for medium- to long-term growth.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | TLM-001 |
| Counterparty | Maruho Co., Ltd. |
| Counterparty overview | Head office: Kita-ku, Osaka; Representative Director and President: Sugita Jun (杉田 淳). Other details: Not disclosed. |
| Relationship with the Company | The trial was conducted by Maruho Co., Ltd., and we received a report confirming completion of the final subject observation. Capital and personnel relationships: Not disclosed. |
| Launch date | 25 June 2026 (actual; date of completion of the final subject observation) |
| Applicable area | Treatment of dry eye disease associated with meibomian gland dysfunction (MGD) |
| Impact on Business Performance | There will be no direct impact on our results for the fiscal year ending March 2027. However, we believe this will contribute to enhancing the value of our pipeline and strengthening the foundation for medium- to long-term growth. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The clinical data required to evaluate efficacy and safety have been collected, and the development strategy will now be reviewed.